Bluebird Bio Withdraws Zynteglo From Germany Over Pricing
Germany Is The Only Country Where the Gene Therapy Was Marketed
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.
You may also be interested in...
The drug-pricing watchdog gave the gene therapy for metachromatic leukodystrophy an “A” grade for use in presymptomatic patients receiving the therapy, which already is approved in Europe.
Biopharma fears that the Joint Clinical Assessment, a first step to harmonizing health technology assessments in the EU, is not fit for purpose for cell and gene therapies and will increase rather than eliminate market access delays.
BioMarin has yet to treat a patient with Roctavian, the first ever hemophilia A gene therapy, eight months after its first approval in Europe, as pricing delays cloud its commercial prospects.